moderna's covid-19 vaccine candidate meets its primary efficacy endpoint in the second interim analysis of the phase 3 cove study
moderna's covid-19 vaccine candidate meets its primary efficacy endpoint in the second interim analysis of the phase 3 cove study
this positive interim analysis from our phase 3 study has given us the first clinical validation that our vaccine can prevent covid-19 disease, including severe disease, said stéphane bancel, chief executive officer of moderna.", "this positive interim analysis from our phase 3 study has given us the first clinical validation that our vaccine can prevent covid-19 disease, including severe disease,\" said stéphane bancel, chief executive officer of moderna.")